MK-2870-005: This study is comparing how safe and effective a new antibody-drug conjugate (called MK-2870) is compared to treatment of the physician's choice in people with endometrial cancer who have had prior platinum-based chemotherapy and immunotherapyA Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)

Summary

Eligible participants will be randomly allocated to one of two treatment arms.

In Arm A (Experimental), participants will receive the investigational drug, called MK-2870. MK-2870 will be given via intravenous (IV) infusion on Day 1 of each 14-day cycle. Additionally, participants receive  diphenhydramine (or equivalent), an H2 antagonist of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to the first 4 infusions of MK-2870. At subsequent infusions, the H2 antagonist and dexamethasone are optional, at the discretion of the investigator.

In Arm B (Active Comparator), participants will receive treatment of physician's choice. This will either be doxorubicin chemotherapy or paclitaxel chemotherapy. Doxorubicin will be given via IV infusion on Day 1 of each 21-day cycle. Paclitaxel will be given by IV infusion on Days 1, 8 and 15 of each 28-day cycle.

Conditions

This trial is treating patients with endometrial cancer who have received prior platinum-based chemotherapy and immunotherapy

More information